Volume 7, Issue 1 supplement | Targeted Oncology

Search all Targeted Oncology articles

Volume 7, Issue 1 supplement

March 2012

Special focus: Biosimilars

Issue Editor:

Mario Dicato

Filter by

Volume:

Sort by

Date published:

New to old Old to new

9 articles in this issue

Biosimilars: Is absence of proof of difference, proof of absence of difference?
M. Dicato
Editorial 16 December 2011 Pages: 1 - 2
Biosimilar rhG-CSFs: how similar are they?
Patricia Gravel
Aarti Naik
Jean-Yves Le Cotonnec
Review 09 February 2012 Pages: 3 - 16
Colony stimulating factors (CSF) biosimilars. Progress?
Florian Scotté
Vincent Launay-Vacher
Jean-Baptiste Rey
Review 17 January 2012 Pages: 17 - 24
Erythropoietin biosimilars currently available in hematology-oncology
Didier Kamioner
Review 18 January 2012 Pages: 25 - 28
Presently available biosimilars in hematology-oncology: G-CSF
Pere Gascon
Review Open access 19 January 2012 Pages: 29 - 34
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
Ludovic Drouet
Review 25 January 2012 Pages: 35 - 42
Risk management of biosimilars in oncology: each medicine is a work in progress
Arnold G. Vulto
Stacy A. Crow
Review Open access 25 January 2012 Pages: 43 - 49
What do prescribers think of biosimilars?
M. S. Aapro
Review 19 January 2012 Pages: 51 - 55
The economic pressures for biosimilar drug use in cancer medicine
Paul Cornes
Perspectives Open access 17 January 2012 Pages: 57 - 67